Real-world data may expand use of targeted drug for hard-to-treat breast cancer
NCT ID NCT06727227
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study follows 138 adults in Bulgaria and Slovenia with HER2-low advanced breast cancer who are taking trastuzumab deruxtecan (T-DXd), a targeted therapy. Researchers will track how long patients go before needing a different treatment or dying. The goal is to see how well T-DXd works in real-world settings, outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that targets HER2-low cancer cells
- What this could lead to
- If successful, this study could confirm that T-DXd works well in everyday clinical practice for people with HER2-low breast cancer, supporting its broader use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment, only tracks existing use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGPanagyurishte, Pazardzhik, 4500, Bulgaria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Research Site
RECRUITINGBurgas, 8000, Bulgaria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Research Site
NOT_YET_RECRUITINGPlovdiv, 4004, Bulgaria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Research Site
ACTIVE_NOT_RECRUITINGSofia, 1303, Bulgaria
-
Research Site
ACTIVE_NOT_RECRUITINGSofia, 1330, Bulgaria
-
Research Site
NOT_YET_RECRUITINGSofia, 1407, Bulgaria
Contact Phone: •••-•••-••••
Contact
-
Research Site
ACTIVE_NOT_RECRUITINGSofia, 1431, Bulgaria
-
Research Site
ACTIVE_NOT_RECRUITINGSofia, 1527, Bulgaria
-
Research Site
NOT_YET_RECRUITINGSofia, 1618, Bulgaria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Research Site
ACTIVE_NOT_RECRUITINGSofia, 1756, Bulgaria
-
Research Site
NOT_YET_RECRUITINGStara Zagora, 6003, Bulgaria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Research Site
ACTIVE_NOT_RECRUITINGVarna, 9003, Bulgaria
-
Research Site
RECRUITINGLjubljana, 1000, Slovenia
Contact Email: •••••@•••••
Contact
-
Research Site
RECRUITINGMaribor, 2000, Slovenia
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?